TrialThe Journal of dermatology2021

Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).

Shinichi Imafuku et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.